It’s been a busy week for Austin-based Everlywell. The healthtech company providing at-home lab tests announced Wednesday it acquired New York-based PWNHealth and Illinois-based Home Access Health Corporation. Terms of the acquisitions were not disclosed.
“The pandemic significantly accelerated the growth of consumer-friendly lab testing ... resulting in a watershed moment for all aspects of diagnostics,” Julia Cheek, CEO and founder of Everlywell, said in a statement. “People now expect affordable, high-quality and easy diagnostic testing more than ever before.”
PWNHealth is a national clinician network focused on improving the early detection and prevention of diseases. The company has partnered with Everlywell since 2016. Home Access Health Corporation informs customers about their health through self-collected lab tests.
The three companies will join forces under the newly formed parent company Everly Health. PWNHealth will rebrand as Everly Health Solutions and operate as an independent subsidiary, according to the release.
“From technology to testing to treatment, Everly Health will transform lives with modern, diagnostics-driven care,” Cheek said. “Our priority is creating a world-class experience that enables our partners to deliver better care with ease.”
Cheek will serve as CEO of Everly Health. PWNHealth’s CEO Sanjay Pingle will work in a transitional role and join the Everly Health board.
Everly Health will remain headquartered in Austin. The company, which now has approximately 500 employees, has a telehealth network covering all 50 states, Puerto Rico and Canada. Together, the three companies plan to hire more than 75 people.
Everlywell also announced a partnership with DoorDash to deliver at-home COVID-19 testing kits on Monday. The kits can be delivered directly to consumers in 12 cities served by DoorDash, according to a news release. Individuals can order a kit through the DoorDash app for $109.
The company initially announced plans to distribute at-home COVID-19 testing kits last March but discontinued the program distributing the tests to healthcare workers instead after the Food and Drug Administration updated its Emergency Use Authorization guidelines. Everlywell received FDA approval under an EUA in February to provide the at-home test kits directly to individuals without the need for a doctor’s prescription.
As more people stayed home last year, the need for at-home lab testing was prevalent. Everlywell saw more than 300 percent growth last year and raised $175 million in early December. The company was founded in 2015 and makes lab tests more accessible through at-home testing for cholesterol, fertility and more health concerns.
